Host: Prathima Setty, MD

Guest: Justin M. Brewer, MD

There are numerous options for pregnancy screening, making the decision of what type of genetic testing to offer your patients more complex. On today’s program, Dr. Justin Brewer will discuss the most important factors for healthcare professionals to consider when screening their pregnant patients. The focus is on non-invasive prenatal testing and carrier screening panels. Dr. Justin Brewer is a practicing OB/GYN and Maternal-Fetal Medicine Specialist at North Mississippi Medical Center in Tupelo, Mississippi. Dr. Brewer is a professional member of the American College of Obstetrics and Gynecology, the Society of Maternal-Fetal Medicine, the American Institute for Ultrasound and Medicine and the Mississippi State Medical Association.

What is hereditary cancer and why is genetic testing important to understand a patient's risk? Cancer is complex and has many causes. Most cancers are sporadic, but about 10 to 15 percent of certain cancers are due to harmful genetic changes called mutations that are passed down through families. Learning whether your patient is at risk for hereditary cancer can help you as a healthcare provider to develop a screening and prevention plan that may help identify cancer at an earlier stage. Because men and women with mutations have a 50% chance of passing their mutation to each of their children, learning about hereditary cancer risk is not only important for your patient, but also their family members. Learn more about Color’s Hereditary Cancer Test and the unique program it offers, including complimentary access to genetic counselors. Learn more about how Color is working with healthcare providers to bring affordable, accessible, and actionable genetic testing to patients at color.com/providers/contact.

Host: John J. Russell, MD

Guest: Jeffrey Klausner, MD, MPH

Sexually Transmitted Infections - in particular, Chlamydia and Gonorrhea - are on the rise in the U.S., presenting some challenges with how these diseases are managed. In this program, host Dr. John Russell will ask guest Dr. Jeffrey Klausner, Professor of Medicine and Public Health at UCLA’s David Geffen School of Medicine, to explain how new diagnostics can aid healthcare providers in the promotion of evidence-based medicine.

Guest: Larissa May, MD, MSPH, MSHS

From 2008-2010 to 2011-2013, there was a 39% increase in the number of visits to Emergency Departments that included an STI diagnosis. Join Dr. Larissa May, Professor of Emergency Medicine and Director of Emergency Antibiotic Stewardship at the University of California-Davis, as she discusses the ever-challenging role Emergency Department's have in STI testing and the solution of an on-demand point of care testing that can reduce time from testing to targeted treatment and patient management.

Host: Kristi Hughes, ND

Guest: David Perlmutter, MD

In this interview, Dr. Kristi Hughes speaks with board-certified neurologist and New York Times bestselling author, David Perlmutter, about effective methods for preventing and treating cognitive decline. Dr. Perlmutter describes how lab tests you are already using can be used to assess patients with cognitive decline and Alzheimer’s disease. He outlines the important roles that systemic inflammation and gut health play in neurodegenerative diseases and discusses treatments that can prevent and even reverse cognitive decline and Alzheimer’s disease. This interview has been brought to you by The Institute for Functional Medicine (www.ifm.org).

Host: Matt Birnholz, MD

Guest: Garry Cutting, MD

Offering cystic fibrosis carrier screening to couples currently planning a pregnancy and to couples seeking prenatal testing has been a standard of care recommended by medical organizations such as ACOG, ACMG, and the NIH. However, recent advances in genome sequencing have expanded our understanding of the genetic basis of cystic fibrosis and enabled us to screen more patients for more CF-causing variants than ever before. Host Dr. Matt Birnholz welcomes Dr. Garry Cutting to address cystic fibrosis carrier screening. Dr. Cutting will provide an academic view on the research-based updates in carrier screening for cystic fibrosis, Dr. Cutting is Aetna/U.S. Healthcare Professor of Medical Genetics and Professor of Pediatrics at Johns Hopkins University School of Medicine. Dr. Cutting's perspectives on CF carrier screening are not on behalf of Quest Diagnostics

Host: Prathima Setty, MD

Guest: Sidney Braman, MD

Guest: Nicola A. Hanania, MD, MS

Guest: Donald Mahler, MD

Device selection for the administration of long-acting bronchodilators is an important factor for the treatment of people diagnosed with COPD. Join Dr. Prathima Setty as she interviews Dr. Sidney Braman, a pulmonologist and Professor at Mount Sinai Health System; Dr. Donald Mahler, a pulmonologist and Emeritus Professor of Medicine at the Geisel School of Medicine at Dartmouth; and Dr. Nicola Hanania, a pulmonologist and Associate Professor of Medicine at the Baylor College of Medicine Airways Clinical Research Center, as they share their insights, including what considerations they evaluate, when selecting treatment and delivery device options for their patients. This promotional, non-CME program is intended for U.S. physicians treating COPD. Dr. Braman and Dr. Mahler are paid consultants of Sunovion Pharmaceuticals Inc. SUNOVION and are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. © 2017 Sunovion Pharmaceuticals Inc. All rights reserved.

Host: Matt Birnholz, MD

Guest: Charlotte A. Gaydos, DrPH, MPH

Misdiagnosis of vaginal infections can lead to inappropriate treatment of vaginal infections, prolong symptoms, and increase an affected woman’s risk of developing serious complications. Clinical procedures and traditional diagnostic techniques are insufficient to accurately diagnose the most common types of vaginal infections. Dr. Charlotte A. Gaydos, Professor of the Division of Infectious Diseases at Johns Hopkins University in Baltimore, Maryland, joins Dr. Matt Birnholz to discuss a validated in vitro diagnostic molecular solution designed to simplify, standardize, and improve the accuracy of vaginal infection diagnosis.

Host: John J. Russell, MD

Guest: Ronald J. Wapner, MD

Guest: Lisa L. Pike-Buchanan, ScM, CGC

Traditional carrier screening based on ethnicity has been a standard approach in maternal fetal medicine, but newer expanded carrier screening methods are redefining that standard for couples considering pregnancy or those who are already pregnant. Joining host, Dr. John Russell, is Dr. Ronald Wapner, Professor of Obstetrics & Gynecology and Maternal Fetal Medicine at Columbia University Medical Center in New York and Lisa Pike-Buchanan, a Genetic Counselor with Quest Diagnostics. They will discuss current insights on expanded carrier screening and evolving technologies and counseling roles.

Host: Mario R. Nacinovich, Jr., MSc

Guest: Christine L. Frissora, MD

What is IBS and why is achieving an accurate diagnosis important for your patients? Health communications professional Mario Nacinovich, Jr., MSc, Managing Partner at AXON Communications, hosts a discussion with recognized IBS expert Dr. Christine L. Frissora about these and other issues. In this interview sponsored by Quest Diagnostics, Dr. Frissora discusses the burden of IBS in the US, including its affect on quality of life for patients, as well as the diagnostic challenges associated with differentiating IBS from other diseases, such as celiac disease. Finally, Dr. Frissora will speak about a new blood test for identifying IBS-D and IBS-M that can finally help provide a proper diagnosis for optimizing treatment for patients. In this expert interview, Dr. Christine L. Frissora will review: The definition of IBS, its etiology, and its epidemiology How IBS is diagnosed and the challenges associated with differentiating IBS from diseases with similar symptomology such as celiac disease, IBD, colitis, and lactose intolerance New tools and resources, including IBSDetexTM™, and when to incorporate such tools into practice IBS symptom management